iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). The Detection segment consists of its advanced image analysis and workflow products, and the Therapy segment consists of its radiation therapy products. The Company sells its products through its direct sales organization, as well as through various original equipment manufacturer partners, distributors and resellers. It develops and markets computer-aided detection (CAD) solutions for digital and film-based mammography systems. Its Axxent SPX Controller includes an optimized skin treatment arm customized for compatibility in confined patient treatment rooms in physician office-based facilities.
Industry, Sector and Symbol:
- Sector: Computer and Technology
- Industry: Computer Peripherals
- Sub-Industry: N/A
- Symbol: NASDAQ:ICAD
- CUSIP: N/A
- Web: www.icadmed.com
Capitalization:- Market Cap: $64.68 million
- Outstanding Shares: 16,374,000
Average Prices:- 50 Day Moving Avg: $4.10
- 200 Day Moving Avg: $4.33
- 52 Week Range: $2.82 - $6.49
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -18.81
- P/E Growth: -0.52
Sales & Book Value:- Annual Revenue: $27.09 million
- Price / Sales: 2.39
- Book Value: $1.58 per share
- Price / Book: 2.50
Profitability:- EBIDTA: ($8,280,000.00)
- Net Margins: -29.61%
- Return on Equity: -38.00%
- Return on Assets: -25.34%
Debt:- Current Ratio: 1.61%
- Quick Ratio: 1.32%
Misc:- Average Volume: 36,903 shs.
- Beta: 1.53
- Short Ratio: 1.09
Frequently Asked Questions for icad inc. (NASDAQ:ICAD)
What is icad inc.'s stock symbol?
icad inc. trades on the NASDAQ under the ticker symbol "ICAD."
How were icad inc.'s earnings last quarter?
icad inc. (NASDAQ:ICAD) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.02. The business earned $6.79 million during the quarter, compared to the consensus estimate of $6.40 million. icad inc. had a negative net margin of 29.61% and a negative return on equity of 38.00%. View icad inc.'s Earnings History.
Where is icad inc.'s stock going? Where will icad inc.'s stock price be in 2017?
1 brokers have issued 12-month target prices for icad inc.'s shares. Their predictions range from $11.00 to $11.00. On average, they expect icad inc.'s share price to reach $11.00 in the next twelve months. View Analyst Ratings for icad inc..
Who are some of icad inc.'s key competitors?
Some companies that are related to icad inc. include Vuzix Corporation (VUZI), ARI Network Services (ARIS), TESSCO Technologies Incorporated (TESS), Marchex (MCHX), Rocket Fuel (FUEL), PC-Tel (PCTI), Attunity (ATTU), Black Box Corporation (BBOX), Points International (PCOM), magicJack VocalTec Ltd (CALL), QuickLogic Corporation (QUIK), DASAN Zhone Solutions (DZSI), Amtech Systems (ASYS), Asure Software (ASUR), Tremor Video (TRMR), Ultralife Corporation (ULBI), IRIDEX Corporation (IRIX) and SITO Mobile (SITO).
Who are icad inc.'s key executives?
icad inc.'s management team includes the folowing people:
- Lawrence Howard, Chairman of the Board
- Kenneth M. Ferry, Chief Executive Officer, Director
- Richard C. Christopher, Chief Financial Officer, Executive Vice President
- Stacey M. Stevens, Senior Vice President - Marketing and Strategy
- Jonathan Go, Senior Vice President - Research and Development
- R. Scott Areglado, Vice President, Corporate Controller
- Andrew Heroux Sassine, Director
- Rachel Brem M.D., Independent Director
- Anthony F. Ecock, Independent Director
- Robert L. Goodman M.D., Independent Director
Who owns icad inc. stock?
icad inc.'s stock is owned by many different of institutional and retail investors. Top institutional investors include
HARBERT DISCOVERY FUND, LP
(6.10%). Company insiders that own icad inc. stock include Kenneth M Ferry and Kevin C Burns. View Institutional Ownership Trends for icad inc..
How do I buy icad inc. stock?
Shares of icad inc. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is icad inc.'s stock price today?
One share of icad inc. stock can currently be purchased for approximately $3.95.
MarketBeat Community Rating for icad inc. (NASDAQ ICAD)MarketBeat's community ratings are surveys of what our community members think about icad inc. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for icad inc. (NASDAQ:ICAD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $11.00 (178.48% upside) |
Analysts' Ratings History for icad inc. (NASDAQ:ICAD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/25/2017 | Laidlaw | Reiterated Rating | Buy | $11.00 | Medium |  |
(Data available from 7/27/2015 forward)
Earnings History for icad inc. (NASDAQ:ICAD)Earnings History by Quarter for icad inc. (NASDAQ ICAD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/4/2017 | Q1 2017 | ($0.20) | ($0.18) | $6.40 million | $6.79 million | View | Listen | |
| 3/8/2017 | Q4 2016 | ($0.17) | ($0.20) | $6.60 million | $6.93 million | View | Listen | |
| 11/2/2016 | Q3 2016 | ($0.14) | ($0.16) | $7.44 million | $6.00 million | View | N/A | |
| 7/27/2016 | Q2 | ($0.14) | ($0.09) | $6.99 million | $7.37 million | View | Listen | |
| 5/3/2016 | Q1 | ($0.14) | ($0.17) | $7.27 million | $6.04 million | View | N/A | |
| 3/1/2016 | Q4 | ($0.17) | ($0.14) | $7.77 million | $7.61 million | View | N/A | |
| 10/29/2015 | Q315 | ($0.07) | ($0.03) | $8.09 million | $9.58 million | View | Listen | |
| 2/24/2015 | Q414 | $0.04 | $0.01 | $13.30 million | $13.20 million | View | N/A | |
| 7/30/2014 | Q2 2014 | ($0.02) | ($0.04) | $9.02 million | $9.67 million | View | N/A | |
| 5/6/2014 | Q1 | ($0.15) | ($0.12) | $7.95 million | $8.50 million | View | Listen | |
| 2/19/2014 | Q4 | ($0.17) | ($0.41) | $8.25 million | $9.14 million | View | Listen | |
| 10/29/2013 | Q313 | ($0.20) | ($0.11) | $8.07 million | $8.30 million | View | Listen | |
| 7/29/2013 | Q2 2013 | ($0.25) | ($0.12) | $7.56 million | $7.71 million | View | Listen | |
| 2/19/2013 | Q4 2012 | | ($0.15) | $6.61 million | $7.82 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for icad inc. (NASDAQ:ICAD)2017 EPS Consensus Estimate: ($0.61)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.19) | ($0.19) | ($0.19) |
| Q2 2017 | 1 | ($0.15) | ($0.15) | ($0.15) |
| Q3 2017 | 1 | ($0.14) | ($0.14) | ($0.14) |
| Q4 2017 | 1 | ($0.13) | ($0.13) | ($0.13) |
(Data provided by Zacks Investment Research)
Dividend History for icad inc. (NASDAQ:ICAD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for icad inc. (NASDAQ:ICAD)Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 24.38%
Insider Trades by Quarter for icad inc. (NASDAQ:ICAD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/14/2016 | Kenneth M Ferry | CEO | Buy | 10,000 | $3.50 | $35,000.00 | |
| 3/4/2016 | Kenneth M Ferry | CEO | Buy | 25,000 | $4.45 | $111,250.00 | |
| 3/4/2016 | Kevin C Burns | CFO | Buy | 10,000 | $4.44 | $44,400.00 | |
| 3/19/2015 | Kenneth M Ferry | CEO | Sell | 100,000 | $10.00 | $1,000,000.00 | |
| 3/12/2015 | Somu Subramaniam | Director | Sell | 50,762 | $9.23 | $468,533.26 | |
| 2/10/2015 | Stacey M Stevens | SVP | Sell | 27,298 | $10.00 | $272,980.00 | |
| 12/3/2014 | Stacey M Stevens | SVP | Sell | 2,502 | $10.00 | $25,020.00 | |
| 12/2/2014 | Stacey M Stevens | SVP | Sell | 503 | $10.01 | $5,035.03 | |
| 12/1/2014 | Stacey M Stevens | SVP | Sell | 299 | $10.00 | $2,990.00 | |
| 11/11/2014 | Kenneth M Ferry | CEO | Sell | 18,318 | $11.09 | $203,146.62 | |
| 11/3/2014 | Stacey M Stevens | VP | Sell | 10,000 | $11.31 | $113,100.00 | |
| 10/1/2014 | Stacey M Stevens | VP | Sell | 13,333 | $10.00 | $133,330.00 | |
| 9/3/2014 | Stacey M Stevens | VP | Sell | 10,000 | $10.94 | $109,400.00 | |
| 8/27/2014 | Kevin C Burns | CFO | Sell | 36,439 | $10.44 | $380,423.16 | |
| 8/25/2014 | Kenneth M Ferry | CEO | Sell | 40,000 | $10.71 | $428,400.00 | |
| 8/20/2014 | Stacey M Stevens | VP | Sell | 5,000 | $10.57 | $52,850.00 | |
| 8/19/2014 | Kenneth M Ferry | CEO | Sell | 20,000 | $10.06 | $201,200.00 | |
| 8/26/2013 | Kenneth M Ferry | CEO | Buy | 5,000 | $5.55 | $27,750.00 | |
| 5/3/2013 | Kevin C Burns | CFO | Buy | 2,900 | $5.19 | $15,051.00 | |
| 8/24/2012 | Kevin C Burns | CFO | Buy | 15,000 | $2.08 | $31,200.00 | |
| 8/17/2012 | Kevin C Burns | CFO | Buy | 28,939 | $2.90 | $83,923.10 | |
(Data available from 1/1/2013 forward)
Headline Trends for icad inc. (NASDAQ:ICAD)
Latest Headlines for icad inc. (NASDAQ:ICAD)
| Source: |
|
| Date | Headline |
|---|
 | Researchers to Present Clinical Data Supporting Use of Xoft System for Endometrial Cancer Treatment at American Association of Physicists in Medicine Annual Meeting & Exhibition
finance.yahoo.com - July 27 at 10:08 PM |
| iCAD announces positive study results comparing use of company’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® to Mohs surgery in treatment of early-stage non-melanoma skin cancer
finance.yahoo.com - July 25 at 8:02 PM |
| Carolina Breast Imaging Specialists Adopts iCAD’s Advanced Artificial Intelligence Technology for Digital Breast 3D Tomosynthesis
finance.yahoo.com - June 6 at 10:59 AM |
| ETFs with exposure to iCAD, Inc. : May 26, 2017
finance.yahoo.com - May 26 at 6:30 PM |
| iCAD, Inc. :ICAD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 25, 2017
finance.yahoo.com - May 25 at 9:03 PM |
| iCAD to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - May 22 at 10:56 AM |
| ICAD: Q1: Strong Detection Offsets Weakness in NMSC Revenue
finance.yahoo.com - May 8 at 5:30 PM |
| First-Ever European Analysis of Electronic Brachytherapy Using the Xoft System for Endometrial and Cervical Cancer Treatment to be Presented at European Society for Radiotherapy & Oncology Meeting
finance.yahoo.com - May 5 at 10:51 PM |
| ICAD: U.S. Tomo Launched, Should Be 2017 Catalyst
finance.yahoo.com - May 5 at 10:51 PM |
 | Preliminary results show targeted treatment offers low toxicity for patients with endometrial or cervical cancer
www.nasdaq.com - May 5 at 5:49 PM |
 | Somewhat Favorable Media Coverage Very Likely to Impact iCAD (ICAD) Share Price
www.americanbankingnews.com - May 4 at 8:50 PM |
| iCAD Inc (ICAD) Posts Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - May 3 at 9:32 PM |
 | Icad reports 1Q loss
www.cnbc.com - May 3 at 5:37 PM |
| Edited Transcript of ICAD earnings conference call or presentation 2-May-17 8:30pm GMT
finance.yahoo.com - May 3 at 5:37 PM |
| iCAD Reports First-Quarter 2017 Financial Results
finance.yahoo.com - May 2 at 4:17 PM |
| Investor Network: iCAD, Inc. to Host Earnings Call
finance.yahoo.com - May 2 at 10:20 AM |
| iCAD Announces First Early-Stage Breast Cancer Patient Treated with Intraoperative Radiation Therapy Using the Xoft System at Monash Cancer Centre, a partnership between Peter MacCallum Cancer Centre and Monash Health in Australia
finance.yahoo.com - May 1 at 1:24 PM |
| iCAD to Showcase Breakthrough Early-Stage Breast Cancer Treatment Utilizing the Xoft System at American …
finance.yahoo.com - April 26 at 7:31 PM |
| iCAD to Showcase Breakthrough Early-Stage Breast Cancer Treatment Utilizing the Xoft System at American Society of Breast Surgeons (ASBrS) Annual Meeting
finance.yahoo.com - April 26 at 7:31 PM |
 | iCAD to Report First Quarter 2017 Financial Results on Tuesday, May 2
feeds.benzinga.com - April 24 at 8:28 AM |
| Researchers to Present Updated Clinical Data on Intraoperative Radiation Therapy Using the Xoft System …
finance.yahoo.com - April 20 at 11:37 AM |
| Researchers to Present Updated Clinical Data on Intraoperative Radiation Therapy Using the Xoft System at American Brachytherapy Society (ABS) Annual Meeting
finance.yahoo.com - April 20 at 11:37 AM |
| iCAD (ICAD) Earning Very Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 15 at 8:58 AM |
| ICAD: Tomo FDA Approval Sets Stage For Next Growth Phase
finance.yahoo.com - April 11 at 5:35 PM |
| ETFs with exposure to iCAD, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 10:22 AM |
| iCAD To Showcase PowerLook Tomo Detection Technology At SBI/ACR Breast Imaging Symposium
finance.yahoo.com - April 7 at 10:22 AM |
| ICAD INC Financials
finance.yahoo.com - March 30 at 6:13 PM |
 | iCAD Cancer Detecting Product Gets FDA Premarket OK (ICAD)
www.investopedia.com - March 27 at 5:26 PM |
| iCAD Cancer Detecting Product Gets FDA Premarket OK
www.investopedia.com - March 27 at 5:26 PM |
| iCAD Receives FDA Approval For PowerLook Tomo Detection
finance.yahoo.com - March 27 at 11:07 AM |
| 8:02 am iCAD announces that PowerLook Tomo Detection has received Premarket Approval from the FDA
finance.yahoo.com - March 27 at 11:07 AM |
| ICAD INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 24 at 5:53 PM |
| ICAD: NMSC Utilization Revenue Ramp Taking Longer
finance.yahoo.com - March 14 at 11:56 AM |
 | iCAD's (ICAD) CEO Ken Ferry on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 9 at 8:55 PM |
| ICAD INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 9 at 8:55 PM |
| iCAD Announces More Than 3,000 Early-Stage Breast Cancer Patients Treated with Intraoperative Radiation Therapy Using the Xoft System
finance.yahoo.com - March 9 at 3:53 PM |
| iCAD Inc (ICAD) Posts Earnings Results
www.americanbankingnews.com - March 9 at 12:21 PM |
| Q4 2016 ICAD Inc Earnings Release - After Market Close
us.rd.yahoo.com - March 8 at 11:36 PM |
| Icad reports 4Q loss
www.cnbc.com - March 8 at 6:36 PM |
| iCAD Showcases Targeted, Non-Surgical Non-Melanoma Skin Cancer Treatment at AAD 2017
finance.yahoo.com - March 3 at 5:49 PM |
| iCAD Showcases Targeted, Non-Surgical Non-Melanoma Skin Cancer Treatment at AAD 2017
finance.yahoo.com - March 3 at 5:49 PM |
| iCAD to Present at the 29th Annual ROTH Conference
finance.yahoo.com - March 2 at 6:12 PM |
| iCAD to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call on Wednesday, March 8, 2017
finance.yahoo.com - February 27 at 6:47 PM |
| ICAD INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets
biz.yahoo.com - February 8 at 6:33 PM |
| ICAD: Certain Catalysts Expected to Return ICAD to Positive Revenue Growth in 2017
finance.yahoo.com - February 8 at 6:33 PM |
| ICAD INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
us.rd.yahoo.com - December 22 at 11:07 PM |
 | 2:12 pm iCAD discloses that Invivo Corp purchased all right, title, & interest to certain intellectual property relating to the VersaVue Software, the DynaCAD product, & related assets for about $3.2 mln
us.rd.yahoo.com - December 22 at 11:07 PM |
 | BRIEF-Icad says entered into asset purchase agreement with Invivo Corp- SEC filing
www.reuters.com - December 22 at 6:06 PM |
| ICAD INC Files SEC form 8-K, Other Events
biz.yahoo.com - December 16 at 6:23 PM |
| First-Ever Analysis of Intraoperative Radiation Therapy with Xoft System as a Boost Prior to Whole Breast …
finance.yahoo.com - December 6 at 10:26 AM |
icad inc. (ICAD) Chart for Thursday, July, 27, 2017
